83 results
Page 3 of 5
PRER14A
1yfsczxqtf
10 Apr 20
Preliminary revised proxy
4:38pm
DEFA14A
EX-2.1
nj6ijsqz kempi
9 Mar 20
Additional proxy soliciting materials
12:00am
8-K
EX-2.1
k77ovw 8h1yh
9 Mar 20
Entry into a Material Definitive Agreement
12:00am
PREM14A
07j dvw60
6 Mar 20
Preliminary proxy related to merger
5:32pm
8-K
EX-2.1
2980rlo
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
tazer5idv xe3ndvc9v
18 Dec 19
Additional proxy soliciting materials
8:11am
CORRESP
kan wdkih
16 Nov 18
Correspondence with SEC
12:00am
8-K
EX-1.1
z8f0ceooqlbooe 9sztr
9 Nov 18
Entry into a Material Definitive Agreement
5:10pm
424B5
gitfomlmtxzx9jxi
9 Nov 18
Prospectus supplement for primary offering
4:49pm
8-K
EX-1.1
7b8teoui9
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
424B5
8gwvlkesvpfpuu
28 Jun 18
Prospectus supplement for primary offering
4:54pm
424B5
li7fj82oc l8vxmh
27 Jun 18
Prospectus supplement for primary offering
4:49pm
8-K
llxb4
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
EX-10.2
c3wp0t
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am